

TFW H11

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	08/932227-Conf. #5092	
	Filing Date	September 17, 1997	
	First Named Inventor	Eric Thor Fossel	
	Art Unit	1711	
	Examiner Name	J. C. Mullis	
Total Number of Pages in This Submission		Attorney Docket Number	S1509.70029US00

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Tani Chen, Sc.D.		
Date	April 5, 2006	Reg. No.	52,728

**Certificate of Mailing Under 37 CFR 1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Dated: 4/5/06

Signature: (Angela M. Griffith)



DOCKET NO.: S1509.70029US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eric T. Fossel  
Serial No.: 08/932,227  
Confirmation No.: 5092  
Filed: September 17, 1997  
For: TOPICAL DELIVERY OF L-ARGININE TO CAUSE  
BENEFICIAL EFFECTS

Examiner: Jeffrey C. Mullis  
Art Unit: 1711

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 5th day of April, 2006.

  
Angela M. Griffith

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.


An early and favorable action is hereby requested.

Serial No.: 08/932,227  
Conf. No.: 5092


- 3 -

Art Unit: 1711

Respectfully submitted,

By:   
Tani Chen, Sc.D., Reg. No. 52,728  
Patrick R.H. Waller, Ph.D., Reg No. 41,418  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: S1509.70029US00  
Date: April 5, 2006  
**xNDDx**



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 08/932,227		ATTY. DOCKET NO.: S1509.70029US00			
				FILING DATE: September 17, 1997		CONFIRMATION NO.: 5092			
				APPLICANT: Eric T. Fossel					
				GROUP ART UNIT: 1711		EXAMINER: Jeffrey C. Mullis			
Sheet	1	of	1						

**OTHER ART – NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Argiolas, A., et al., "Nitric Oxide is a Central Mediator of Penile Erection," <i>Neuropharmacology</i> , Vol. 11, pp. 1339-1344 (1994).	
		Bunker, C.D., "Alteration in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia," <i>Correspondence</i> , pp. 669.	
		DeBoer, E.M., "Does Topical Minoxidil Increase Skin Blood Flow? A Laser Doppler Flowmetry Study," <i>Acta Derm Venereo</i> , Vol. 68, pp. 271-274 (1988).	
		Dietz, N. M., "Is nitric oxide involved in cutaneous vasodilation during body heating in humans?," <i>J. Appl. Physiol.</i> , Vol. 76, No. 5, pp. 2047-2053 (1994).	
		Garban, H., "Effect of aging on nitric oxide-mediated penile erection in rats," <i>Am. J. Physiol.</i> , Vol 268, pp. 467-475 (1995).	
		I-Sheng, T., "Evaluation of Vasulogenic Impotence Using Dynamic Penile Washout Test," <i>J. Formosan Med. Assoc.</i> , Vol. 89, No. 11, pp. 992-996 (1990).	
		Kirkeby, H.J., "Role of the L-arginine/nitric oxide pathway in relaxation of isolated human penile cavernous tissue and circumflex veins," <i>Acta Physiol Scand</i> , Vol. 149, pp. 385-392 (1993).	
		Klemp, P., "Subcutaneous Blood Flow in Early Male Patter Baldness," <i>J. Invest Dermatol</i> , Vol. 92, pp. 725-726 (1989).	
		Laan, E., et al., "Assessment of female sexual arousal: Response specificity and construct validity," <i>Psychophysiology</i> , Vol. 32, pp. 476-485 (1995).	
		Mathias, B. J. et al., "Topical Capsaicin for Chronic Neck Pain," <i>Am. J. Phys. Med. Rehabil.</i> , Vol. 74, No. 1, pp. 39-44 (1995).	
		Moody, J.A., et al., "Effects of Long-Term Oral Administration of L-Arginine on the Rat Erectile Response," <i>American Urological Association, Inc.</i> , Vol. 158, pp. 942-947 (1997).	
		Owen, J.A., et al., "Topical Nitroglycerin: A Potential Treatment for Impotence," <i>The Journal of Urology</i> , Vol. 141, pp. 546-548 (1989).	
		Singh, S. et al., "Response to digital arteries to endothelium dependent and independent vasocilators in patients with Raynaud's phenomenon," <i>European Journal of Clinical Investigation</i> , Vol. 25, pp. 182-185 (1995).	
		Sonntag, M., et al., "Role of nitric oxide in local blood flow control in the anaesthetized dog," <i>European Journal of physiology</i> , pp. 194-199 (1992).	
		Tseng, L.F., et al., "Increase of nitric oxide production by L-arginine potentiates i.c.v. administered $\beta$ -endorphin-induced antinociception in the mouse," <i>European Jouranal of Pharmacology</i> , Vol. 212, pp. 301-303 (1992).	
		Wang, R. et al., "Nitric Oxide Mediates Penile Erection in Cats," <i>The Journal of Urology</i> , Vol. 151, pp. 234-237 (1994).	
		Whitmore, S.E., et al, "Acute Effect of Topical Minoxidil on Digital Blood Flow in Patients with Raynaud's Phenomenon," <i>The Journal of Rheumatology</i> , Vol. 11, No. 1, pp. 50-54 (1995).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether ornot citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by orsubmitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]